SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 84 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $5 | -100.0% | 212 | -77.7% | 0.00% | – |
Q1 2022 | $16,000 | -69.8% | 951 | -60.9% | 0.00% | – |
Q4 2021 | $53,000 | +76.7% | 2,435 | +80.1% | 0.00% | – |
Q4 2020 | $30,000 | -95.7% | 1,352 | -97.1% | 0.00% | -100.0% |
Q2 2020 | $691,000 | +215.5% | 46,663 | +132.8% | 0.00% | – |
Q1 2020 | $219,000 | -38.8% | 20,046 | -50.9% | 0.00% | -100.0% |
Q4 2019 | $358,000 | +411.4% | 40,826 | +441.2% | 0.00% | – |
Q2 2019 | $70,000 | +288.9% | 7,544 | +119.9% | 0.00% | – |
Q1 2019 | $18,000 | +200.0% | 3,430 | +122.2% | 0.00% | – |
Q4 2018 | $6,000 | -95.9% | 1,544 | -91.6% | 0.00% | – |
Q3 2018 | $148,000 | +4833.3% | 18,438 | +3609.9% | 0.00% | – |
Q2 2018 | $3,000 | – | 497 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |